Investing.com -- Barclays downgraded Illumina Inc (NASDAQ:ILMN) to "Underweight" given growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in consumables demand.
The firm said these factors raise concerns about management’s ability to meet long-term revenue projections. "we struggle to see how shares would perform with the rest of the group over the rest of the year," analysts wrote in a note.
Barclays (LON:BARC) lowered its price target to $100 from a prior $130. The firm warned that further multiple contraction is possible if China revenues decline materially.
While acknowledging Illumina’s technological edge, Barclays characterized the company as a mature tools business comparable to other genomics and proteomics firms, which typically exhibit mid-single-digit growth and mid-20% operating margins.
Related Articles
Barclays downgrades Illumina on China risks, competition
Amphenol Corp. ratings upgraded to 'A-' by S&P Global on strong business performance
McDonald's international markets prop up sales growth even as US lags
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。